Article

Cleveland Clinic finds AMD animal model

A Cleveland Clinic research team has developed the first animal model of age-related macular degeneration (AMD), and it is expected to enable researchers to study the development and progression of AMD and conduct pre-clinical testing of new therapeutics.

Cleveland-A Cleveland Clinic research team has developed the first animal model of age-related macular degeneration (AMD), and it is expected to enable researchers to study the development and progression of AMD and conduct pre-clinical testing of new therapeutics.

The research team, led by Joe G. Hollyfield, PhD, of the institution's Cole Eye Institute, modified specific proteins found in mouse blood so that the mouse's immune system was forced to mount a response. This response causes the mouse to display characteristics of AMD in a short amount of time.

Specifically, Dr. Hollyfield and his team immunized mice with mouse serum albumin adducted with oxidation fragments of the long-chain fatty acid known as docosahexaenoic acid. Earlier studies by this group found that the fragments were localized in drusen from donor eye tissues and in plasma samples from patients with AMD. The immunized mice develop antibodies to the oxidation fragment, deposit complement in the outer eye wall, accumulate drusen below the retinal pigment epithelium, and show features of geographic atrophy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.